Improved Survival But More Adverse Events Seen for Women With Cancer
via HealthDayWEDNESDAY, March 18, 2026 -- Female cancer patients have increased survival but also have a higher risk for serious and adverse side effects from cancer treatment compared with men, according to a study published online Feb. 16 in the Journal of the National Cancer Institute.
Rakchha Chhetri, from Flinders University in Adelaide, Australia, and colleagues examined the association between patient sex and overall survival (OS), progression-free survival (PFS), and grade ≥3 adverse events (AEs) in a pooled individual participant data meta-analysis involving 20,806 participants from 39 phase 2 to 3 trials supporting U.S. Food and Drug Administration approvals of anticancer medicines for advanced solid tumors.
The researchers found that female sex was associated with significantly improved OS and PFS (hazard ratios, 0.79 and 0.84, respectively) in trials across 12 tumor types. However, women also had increased risk for grade ≥3 AEs (hazard ratio, 1.12).
"If women are living longer but experiencing more severe side effects, we need to acknowledge that and respond to it," lead author Natansh D. Modi, Ph.D., from the University of South Australia in Adelaide, said in a statement. "At the same time, we need to better understand why male patients appear to have poorer survival."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-03-19 01:54
Read more
- Trump Order Backing Popular Weedkiller, Glyphosate, Sparks Backlash From MAHA
- Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
- Laser Red-Light Therapy Delivers Irradiance Levels Exceeding Safety Limits
- Doctors Warn Patients to Research Cosmetic Surgery Providers Before Getting Work Done
- Single Off-Label Adderall Dose Tied to Measurable Cardiovascular Effects
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions